Emerging cancer cases across the globe and treating them with conventional therapies with
multiple limitations have been challenging for decades. Novel drug delivery systems and …

Cancer theragnostics is a novel approach that combines diagnostic imaging and
radionuclide therapy. It is based on the use of a pair of radiopharmaceuticals, one optimized …

Precision medicine and personalized medicine are two approaches to healthcare that aim to
tailor medical treatments and interventions to individual patients. These approaches are …

Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs) have recently emerged
as a focal point in global nuclear medicine, underscored by their promising applications in …

Abstract Purpose of Review This paper aims to address the latest findings in
neuroendocrine tumor (NET) theranostics, focusing on new evidence and future directions of …

In a recent study, the authors developed a nectin-4–targeting bicyclic peptide–based
radiotracer, 68Ga-N188, for PET imaging of advanced urothelial cancer. Preclinical …

Introduction Prostate specific membrane antigen (PSMA), highly expressed in metastatic
castration-resistant prostate cancer (mCRPC), is an established therapeutic target …

Preclinical studies are essential for effectively evaluating TAT radiopharmaceuticals. Given
the current suboptimal supply chain of these radionuclides, animal studies must be refined …

Simple Summary Low-dose radiation delivered by radionuclides stimulates an immune
response against cancer. We hypothesize that this type of low-dose radiation can potentiate …

Background In the rapidly evolving field of nuclear medicine, the paramount importance of
radiation protection, safety, and quality systems cannot be overstated. This document …